While still early, it is possible that they and/or others could pivot to autoimmune diseases instead. The bar is (a lot) lower. Vivacta Bio, a Grit Bio spin out raised a $22 million seed round and is currently seeking to raise another tens of millions to fund its future clinical work.
Market Data 
Markets 
AI
